Inhibitory CCK+ basket synapse defects in mouse models of dystroglycanopathy
- PMID: 38179984
- PMCID: PMC10942650
- DOI: 10.7554/eLife.87965
Inhibitory CCK+ basket synapse defects in mouse models of dystroglycanopathy
Abstract
Dystroglycan (Dag1) is a transmembrane glycoprotein that links the extracellular matrix to the actin cytoskeleton. Mutations in Dag1 or the genes required for its glycosylation result in dystroglycanopathy, a type of congenital muscular dystrophy characterized by a wide range of phenotypes including muscle weakness, brain defects, and cognitive impairment. We investigated interneuron (IN) development, synaptic function, and associated seizure susceptibility in multiple mouse models that reflect the wide phenotypic range of dystroglycanopathy neuropathology. Mice that model severe dystroglycanopathy due to forebrain deletion of Dag1 or Pomt2, which is required for Dystroglycan glycosylation, show significant impairment of CCK+/CB1R+ IN development. CCK+/CB1R+ IN axons failed to properly target the somatodendritic compartment of pyramidal neurons in the hippocampus, resulting in synaptic defects and increased seizure susceptibility. Mice lacking the intracellular domain of Dystroglycan have milder defects in CCK+/CB1R+ IN axon targeting, but exhibit dramatic changes in inhibitory synaptic function, indicating a critical postsynaptic role of this domain. In contrast, CCK+/CB1R+ IN synaptic function and seizure susceptibility was normal in mice that model mild dystroglycanopathy due to partially reduced Dystroglycan glycosylation. Collectively, these data show that inhibitory synaptic defects and elevated seizure susceptibility are hallmarks of severe dystroglycanopathy, and show that Dystroglycan plays an important role in organizing functional inhibitory synapse assembly.
Keywords: Dystroglycan; axon guidance; hippocampus; inhibitory neuron; mouse; neuroscience; seizure; synapse formation.
Conflict of interest statement
JJ, DM, MK, ES, KW No competing interests declared
Figures




















Update of
- doi: 10.1101/2022.01.26.477791
- doi: 10.7554/eLife.87965.1
- doi: 10.7554/eLife.87965.2
Similar articles
-
Neuronal Dystroglycan Is Necessary for Formation and Maintenance of Functional CCK-Positive Basket Cell Terminals on Pyramidal Cells.J Neurosci. 2016 Oct 5;36(40):10296-10313. doi: 10.1523/JNEUROSCI.1823-16.2016. J Neurosci. 2016. PMID: 27707967 Free PMC article.
-
The many roles of dystroglycan in nervous system development and function: Dystroglycan and neural circuit development: Dystroglycan and neural circuit development.Dev Dyn. 2023 Jan;252(1):61-80. doi: 10.1002/dvdy.516. Epub 2022 Jul 18. Dev Dyn. 2023. PMID: 35770940 Review.
-
Neuronal Dystroglycan regulates postnatal development of CCK/cannabinoid receptor-1 interneurons.Neural Dev. 2021 Aug 6;16(1):4. doi: 10.1186/s13064-021-00153-1. Neural Dev. 2021. PMID: 34362433 Free PMC article.
-
NAD+ improves neuromuscular development in a zebrafish model of FKRP-associated dystroglycanopathy.Skelet Muscle. 2019 Aug 7;9(1):21. doi: 10.1186/s13395-019-0206-1. Skelet Muscle. 2019. PMID: 31391079 Free PMC article. Review.
-
Residual laminin-binding activity and enhanced dystroglycan glycosylation by LARGE in novel model mice to dystroglycanopathy.Hum Mol Genet. 2009 Feb 15;18(4):621-31. doi: 10.1093/hmg/ddn387. Epub 2008 Nov 18. Hum Mol Genet. 2009. PMID: 19017726 Free PMC article.
Cited by
-
Characterization of Dystrophin Dp71 Expression and Interaction Partners in Embryonic Brain Development: Implications for Duchenne/Becker Muscular Dystrophy.Mol Neurobiol. 2025 May;62(5):6256-6272. doi: 10.1007/s12035-024-04676-6. Epub 2025 Jan 6. Mol Neurobiol. 2025. PMID: 39760982
-
Distinct functional domains of Dystroglycan regulate inhibitory synapse formation and maintenance in cerebellar Purkinje cells.bioRxiv [Preprint]. 2024 Aug 30:2024.08.29.610348. doi: 10.1101/2024.08.29.610348. bioRxiv. 2024. Update in: Commun Biol. 2025 Jun 5;8(1):878. doi: 10.1038/s42003-025-08323-1. PMID: 39257744 Free PMC article. Updated. Preprint.
-
UDP-glucose dehydrogenase variants cause dystroglycanopathy.Ann Clin Transl Neurol. 2025 Jun;12(6):1302-1308. doi: 10.1002/acn3.70002. Epub 2025 Apr 17. Ann Clin Transl Neurol. 2025. PMID: 40245099 Free PMC article.
-
Distinct functional domains of Dystroglycan regulate inhibitory synapse formation and maintenance in cerebellar Purkinje cells.Commun Biol. 2025 Jun 5;8(1):878. doi: 10.1038/s42003-025-08323-1. Commun Biol. 2025. PMID: 40473926 Free PMC article.
References
-
- Al Dhaibani M, El-Hattab A, Ismayl O, Suleiman J. B3GALNT2-related dystroglycanopathy: expansion of the phenotype with novel mutation associated with muscle-eye-brain disease, walker–warburg syndrome, epileptic encephalopathy-west syndrome, and sensorineural hearing loss. Neuropediatrics. 2018;49:289–295. doi: 10.1055/s-0038-1651519. - DOI - PubMed
-
- Berghuis P, Rajnicek AM, Morozov YM, Ross RA, Mulder J, Urbán GM, Monory K, Marsicano G, Matteoli M, Canty A, Irving AJ, Katona I, Yanagawa Y, Rakic P, Lutz B, Mackie K, Harkany T. Hardwiring the brain: endocannabinoids shape neuronal connectivity. Science. 2007;316:1212–1216. doi: 10.1126/science.1137406. - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous